Clinical trial NCT06040632: IMPROVE-pT1: Accurate Allocation of Completion Resection in Early Colorectal Cancer
Official title: Accurate Allocation of Completion Resection in Early Colorectal Cancer: an Observational Cohort Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Colorectal Cancer
Colorectal Polyp
Colorectal Cancer Stage I
Lead sponsor: University of Aarhus
Sponsor class: OTHER
Collaborators: name: Copenhagen University Hospital at Herlev
name: Regionshospitalet Horsens
name: Aarhus University Hospital
name: Regional Hospital Randers
First posted: 2023-09-15
Enrollment: 67
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients having undergone local resection of pT1 colorectal cancer and with planned completion resection, as recommended by the local MDT board

Brief summary: After introducing a nationwide screening program for colorectal cancer (CRC) in Denmark, more cases of early-stage CRC are being detected. Cancers in the earliest stages are often removed locally, either during the diagnostic colonoscopy or through planned minimally invasive surgery.

This early detection of cancer, and thereby an improved prognosis, is a positive feature but has also introduced a new clinical dilemma. Is the patient fully cured by the local resection, or do they need further surgery? Whether further surgery is recommended at the Multi-Disciplinary Team (MDT) board meeting depends on the outcome of specific criteria from the histopathological assessment of the locally removed specimen.

The presence of these criteria does not, however, translate directly into the presence of residual disease - merely into a theoretically increased risk. In Denmark, after surgery, the fraction of cases with residual disease has been around 15% for many years. In the remaining 85% of cases, local removal alone was curative - and the surgery appears excessive.

Investigating blood samples for the presence of circulating tumor DNA (ctDNA) is a new and promising method for cancer detection. The method utilizes that cancer cells release ctDNA into the circulation. ctDNA detected in blood drawn from a patient a few days after local removal of a tumor indicates that residual disease is present and further treatment, such as surgery, is needed.

The purpose of this study is to investigate, whether analyses of ctDNA can correctly identify patients with residual disease after local removal of early CRC. If this identification proves accurate, many patients can be spared further surgery.

Detailed description: KEY POINTS

* 85% of patients receiving completion bowel resection after local removal of pT1 CRC are overtreated.
* ctDNA is a biomarker of residual cancer disease and could help identify those patients, where completion bowel resection is necessary, sparing those that are already cured.

GOALS ● To explore ctDNA analysis for identification of the patient subgroup with residual disease after local excision of pT1 tumors and hence need for completion resection.

PERSPECTIVES

● Practice-changing evidence for ctDNA-guided risk-stratification for pT1 CRCs after local excision, an important and well-recognized clinical dilemma in the management of CRC.

PROJECT DESCRIPTION After the introduction of the nationwide screening program for CRC in Denmark, the number of very early-stage CRC cases (pT1) has increased. Many of these early cancers present macroscopically as polyps and are removed by local excision. Despite the early detection leading to improved prognosis, locally resected pT1 CRC presents a clinical dilemma, due to the small, but significant, risk of regional lymph node metastasis. This introduces the question: Was the patient cured by local resection alone? - or is segmental bowel resection (termed completion resection) required to remove metastatic regional lymph nodes and cure the patient? The present guideline for managing this clinical situation has led to massive overtreatment. Resection is recommended if the local excision was non-radical or if the histopathological assessment revealed ≥1 histopathological risk factor. However, only 15% of the patients receiving completion resection are diagnosed with metastatic lymph nodes. For the remaining 85%, the local excision was curative, and the completion resection was an overtreatment. Each year in Denmark, 130 colon and 40 rectal completion resections are performed. The complication rate after bowel resection is substantial. Following colonic resections 11% of patients suffer from surgical complications, 7% from medical complications, and 4% from a combination of both. For rectal cancer resection, the corresponding fractions are 20%, 5%, and 5%, respectively. The associated overall 30-day mortality is 1.3%, rising to 1.5% after surgical complications and to 11% after medical or combined complications. Furthermore, many patients suffer from long-term or even chronic postoperative morbidities and late organ effects such as pain, bowel obstruction, and hernia formation.

This highlights the significant importance of accurately choosing patients who indeed require completion resection for a definite cure.

In the current study the use of ctDNA will be explored for identification of the patient subgroup with residual disease after local excision of pT1 tumors and, hence, the need for completion resection.

The hypotheses are (1) ctDNA can be used to identify patients with residual disease requiring completion resection and (2) patients without detectable ctDNA were cured by the local resection, and therefore can be spared completion resection.

Investigators will conduct a prospective, observational feasibility study, assessing the association between pre-completion-resection ctDNA status and the presence of residual disease established by pathological evaluation of the resected specimen. A total of 67 patients, who have undergone local resection of pT1 CRC and who are planned to receive a completion resection will be included. Blood samples will be collected before the completion resection. Tumor tissue will be obtained from the locally resected pT1 tumor.

ctDNA analysis will be performed using the recently published whole genome sequencing-based MRDetect approach.

Feasibility measures: 1) recruitment of \>30 patients every 6 months, 2) a ctDNA positivity rate ≥70%, and 3) accuracy of ctDNA status predicting lymph node status. Using the pathology evaluation of the completion resection specimen as gold standard.

If the performance criteria are met, the study will be transitioned into an open-label 1:1 randomized trial comparing the effect of ctDNA-guided patient selection for completion resection to current practice, which is completion resection to all. If the performance criteria are not met, the method will be re-evaluated to optimize sensitivity.

Eligibility criteria: Inclusion Criteria:

* Patients having undergone local resection of pT1 colorectal cancer and with planned completion resection, as recommended by the local MDT board

  * The reason for the planning of completion resection may be non-micro radical tumor removal, piece-meal resection making assessment of resection margin impossible or the presence of one or more histological risk factors

Exclusion Criteria:

* Patients not able to understand information about the study and/or give informed consent
* Patients not accepting blood samples stored in biobank
* Cases with non-obtainable primary tumor tissue, required for the conduction of mutational analyses
* Other recent (within 5 years) or current malignant disease, except basocellular carcinoma of the skin
* Planned completion resection due to other factors, such as patient's wish or hereditary disposition for CRC, and with the absence of risk factors mentioned above
* Withdrawal of consent

Primary outcomes:
measure: ctDNA analysis
timeFrame: After recruitment of the last patient, we expect that ctDNA analyses can be performed within 6 months
Secondary outcomes:
measure: Pathological evaluation of the resected specimen from the completion resection
timeFrame: After recruitment of the last patient, these data will be available (expected in spring 2024)
measure: 30- and 90-day mortality related to the completion resection
timeFrame: These data will be extracted from the patient's medical records 3 months after surgery
measure: Postoperative morbidities
timeFrame: After recruitment of the last patient, these data will be extracted from the patient's medical records within 6 months
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Bispebjerg Hospital
state: Capital Region Of Denmark
city: Herlev
country: Denmark
facility: Herlev Hospital
state: Capital Region Of Denmark
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
state: Central Denmark Region
city: Herning
country: Denmark
facility: Gødstrup Hospital
state: Central Denmark Region
city: Horsens
country: Denmark
facility: Regional Hospital Horsens
state: Central Denmark Region
city: Randers
country: Denmark
facility: Regional Hospital Randers
state: Central Denmark Region
city: Viborg
country: Denmark
facility: Regional Hospital Viborg
state: Central Denmark Region
city: Aalborg
country: Denmark
facility: Aalborg University Hospital
state: North Denmark Region
city: Odense
country: Denmark
facility: Odense University Hospital
state: The Region Of Southern Denmark
Study officials:
affiliation: Copenhagen University Hospital at Herlev
name: Mads F Klein, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Copenhagen University Hospital at Herlev
name: Jeppe Kildsig, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Regionshospitalet Horsens
name: Kåre A Gotschalck, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Regional Hospital Randers
name: Anne-Sofie Kannerup, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Aarhus University Hospital
name: Lene H Iversen, MD, DMSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, Maloney D, Patel K, Liao W, Widman AJ, Wong P, Callahan MK, Ha G, Reed S, Rotem D, Frederick D, Sharova T, Miao B, Kim T, Gydush G, Rhoades J, Huang KY, Omans ND, Bolan PO, Lipsky AH, Ang C, Malbari M, Spinelli CF, Kazancioglu S, Runnels AM, Fennessey S, Stolte C, Gaiti F, Inghirami GG, Adalsteinsson V, Houck-Loomis B, Ishii J, Wolchok JD, Boland G, Robine N, Altorki NK, Landau DA. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020 Jul;26(7):1114-1124. doi: 10.1038/s41591-020-0915-3. Epub 2020 Jun 1.